Trial Profile
A Randomised Controlled Trial Comparing the Efficacy of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir (LPV/r) Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary) ; Lamivudine
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms PROMISE-PEP
- 25 Sep 2020 Results (n=164) assessing antiretroviral treatment and its effect on oral health outcomes in 5 to 7 year old Ugandan children, published in the Medicine
- 18 Feb 2020 Results published in the Clinical Infectious Diseases
- 07 Mar 2018 Results (n=151) assessing the mitochondrial toxicity of 3TC or LPV/r regimens after 1 year of PrEP among HIV-exposed uninfected infants, were presented at the 25th Conference on Retroviruses and Opportunistic Infections.